Trial · NCT00035932
Registered outcomes45
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 45
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in HIV Ribonucleic Acid (RNA) at Week 24 | Baseline, Week 24 | |
| Primary | Mean Change From Baseline in HIV RNA at Week 48 | Baseline, Week 48 | |
| Primary | Mean Change From Baseline in HIV RNA at Week 96 | Baseline, Week 96 | |
| Secondary | Mean Change From Baseline in HIV RNA at Week 2 | Baseline, Week 2 | |
| Secondary | Participants Achieving Virologic Half Log Suppression (Limit of Quantification [LOQ] = 400 c/mL) at Week 24 (Overall and by Protease Inhibitor [PI] Sensitivity) | Baseline, Week 24 | Number of participants with a \>=0.5 log10 decrease in HIV RNA from baseline or HIV RNA \< 400 c/mL at Week 24, by their baseline phenotypic sensitivity to their randomized PI. |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 48, (Overall and by PI Sensitivity) | Baseline, Week 48 | Number of participants with a \>=0.5 log10 decrease in HIV RNA from baseline or HIV RNA \< 400 c/mL at Week 48, by their baseline phenotypic sensitivity to their randomized PI. |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 400 c/mL) at Week 96 | Baseline, Week 96 | Number of participants with a \>=0.5 log10 decrease in HIV RNA from baseline or HIV RNA \< 400 c/mL at Week 96. |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24 | Week 24 | |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 24, by PI Sensitivity | Baseline, Week 24 | Number of participants with a \>=0.5 log10 decrease in HIV RNA from baseline or HIV RNA \< 50 c/mL at Week 24, by their baseline phenotypic sensitivity to their randomized PI. |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 48 | Week 48 | |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 48, by PI Sensitivity | Baseline, Week 48 | Number of participants with a \>=0.5 log10 decrease in HIV RNA from baseline or HIV RNA \< 50 c/mL at Week 48, by their baseline phenotypic sensitivity to their randomized PI. |
| Secondary | Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96 | Week 96 | |
| Secondary | Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 24 | Week 24 | Treatment Response = confirmed suppression to LOQ (400 c/mL). The Algorithm for Treatment Response Without Prior Failure (TRPWF) = participants staying in response at the analysis timepoint without having an intervening, confirmed rebound. |
| Secondary | Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 48 | Week 48 | Treatment Response = confirmed suppression to LOQ (400 c/mL). The Algorithm for Treatment Response Without Prior Failure (TRPWF) = participants staying in response at the analysis timepoint without having an intervening, confirmed rebound. |
| Secondary | Participants Achieving Treatment Response (LOQ = 400 c/mL) Without Prior Failure at Week 96 | Week 96 | Treatment Response = confirmed suppression to LOQ (400 c/mL). The Algorithm for Treatment Response Without Prior Failure (TRPWF) = participants staying in response at the analysis timepoint without having an intervening, confirmed rebound. |
| Secondary | Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 24 | Week 24 | Treatment Response = confirmed suppression to LOQ (50 c/mL). The Algorithm for Treatment Response Without Prior Failure (TRPWF) = participants staying in response at the analysis timepoint without having an intervening, confirmed rebound. |
| Secondary | Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 48 | Week 48 | Treatment Response = confirmed suppression to LOQ (50 c/mL). The Algorithm for Treatment Response Without Prior Failure (TRPWF) = participants staying in response at the analysis timepoint without having an intervening, confirmed rebound. |
| Secondary | Participants Achieving Treatment Response (LOQ = 50 c/mL) Without Prior Failure at Week 96 | Week 96 | Treatment Response = confirmed suppression to LOQ (50 c/mL). The Algorithm for Treatment Response Without Prior Failure (TRPWF) = participants staying in response at the analysis timepoint without having an intervening, confirmed rebound. |
| Secondary | Change From Baseline in CD4 Cell Count at Week 24 | Baseline, Week 24 | |
| Secondary | Change From Baseline in CD4 Cell Count at Week 48 | Baseline, Week 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00035932/registered